Photo from wikipedia
Invasive disease‐free survival (IDFS) rates are excellent in patients with breast cancer (BC) with hormone receptor‐positive (HR+), human epidermal growth factor receptor 2‐negative (HER2‐), axillary lymph node‐negative (LN‐) tumors with… Click to show full abstract
Invasive disease‐free survival (IDFS) rates are excellent in patients with breast cancer (BC) with hormone receptor‐positive (HR+), human epidermal growth factor receptor 2‐negative (HER2‐), axillary lymph node‐negative (LN‐) tumors with a 21‐gene expression assay recurrence score (RS) of 0 to 10. However, to the authors' knowledge, the outcomes among patients with an RS of 11 to 25 who are treated with endocrine therapy alone are unknown.
Keywords:
cancer;
expression assay;
gene expression;
breast cancer
Journal Title: Cancer
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!